The plastic surgery industry has always been one of transition and innovation. From its early days in the 1980s when liposuction first started becoming popular to the minimally invasive and natural-result producing treatments available these days, there are procedures that cater to nearly every body type and aesthetic goal, whether the issue at hand is cosmetic or medical.
Every day, researchers and plastic surgeons like Dr. David Shafer are working to create better procedures that will lead to more natural-looking results, fewer complications and faster recovery time for patients. But as new treatments are being developed, one thing that must remain at the top of every plastic surgeon’s list – safety.
Safety has always been the top priority for New York plastic surgeon Dr. David Shafer. Having created the world’s very first 3D technology for simulated plastic surgery procedure results, called the Vectra XT 3D Imaging System, and the first-ever iPhone plastic surgery app, Dr. Shafer has always been at the forefront of innovation in the field of plastic surgery and strives to improve a patient’s experience and results through research and advancements in technology.
Earlier this year, Dr. Shafer’s exceptional work and passion for plastics surgery and patient satisfaction was noted by the high-tech New York healthcare company Aquavit Pharmaceuticals, Inc. As a result, to lead the company’s medical technology pipeline development in March and now, a recent partnership between Aquavit and another top medical company will allow Dr. Shafer the ability to offer an even safer future in treatments for plastic surgery patients.
Aquavit Pharmaceuticals, Inc. has just signed a definitive licensing agreement with the South Korean medical technology device company, U-Bio Med Inc. (Ubiquitous Bio Medical Equipment) to commercialize the company’s innovative microneedle technology worldwide.
The microneedle product, AQT-001, is unique in its exceptional capacity for direct drug delivery. Made with pure gold to ensure optimal quality and safety, the minuscule size of the microneedles ensures a more effective and rapid delivery of a drug and is much less painful for the patient.
As part of the agreement, Aquavit will have the exclusive right to license, improve and commercialize the microneedle technology. The company has already registered AQT-001 with the FDA (Food and Drug Administration) and is working on registration with the CE (Conformité Européenn) for specialized use. The microneedle technology will soon become available for commercial use in the United States and other countries around the world.
Current and prospective patients at Shafer Plastic Surgery can expect enhanced results for several procedures with the microneedle technology Dr. Shafer is working on with Aquavit.
“It is an innovative delivery system for botulinum toxins and dermal fillers,” explained Dr. Shafer. “I use it with Botox, hyaluronic acid-based fillers and vitamin combinations.”
If you have considered undergoing Botox injections, dermal fillers or any other subcutaneous revitalization treatment, consult with Dr. Shafer to discuss the microneedle procedure and the best options for you to achieve optimal results.
